AARTIPHARM Stock Overview
Primarily engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Aarti Pharmalabs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹608.75 |
| 52 Week High | ₹638.75 |
| 52 Week Low | ₹320.30 |
| Beta | 0 |
| 1 Month Change | 17.13% |
| 3 Month Change | 18.10% |
| 1 Year Change | 70.73% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 111.19% |
Recent News & Updates
Estimating The Intrinsic Value Of Aarti Pharmalabs Limited (NSE:AARTIPHARM)
Apr 19
These 4 Measures Indicate That Aarti Pharmalabs (NSE:AARTIPHARM) Is Using Debt Reasonably Well
Mar 21Shareholder Returns
| AARTIPHARM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.2% | 1.9% | 2.9% |
| 1Y | 70.7% | 62.5% | 45.3% |
Return vs Industry: AARTIPHARM exceeded the Indian Pharmaceuticals industry which returned 62.5% over the past year.
Return vs Market: AARTIPHARM exceeded the Indian Market which returned 45.3% over the past year.
Price Volatility
| AARTIPHARM volatility | |
|---|---|
| AARTIPHARM Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.5% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: AARTIPHARM's share price has been volatile over the past 3 months.
Volatility Over Time: AARTIPHARM's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 2,042 | Hetal Gala | www.aartipharmalabs.com |
Aarti Pharmalabs Limited primarily engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates in India and internationally. Its APIs and intermediates are used in various therapeutic areas, including anti-hypertensive, anti-asthmatic, anti-cancer, central nervous system (CNS) agents, skincare, decongestant, cardiovascular, anti-thalassemic, analgesic, anti-diabetic, and ophthalmologic medications. The company also develops new chemical entities (NCE), regulatory starting materials (RSM), basic starting materials, key starting materials (KSM), key building blocks, xanthine derivatives, and allied products.
Aarti Pharmalabs Limited Fundamentals Summary
| AARTIPHARM fundamental statistics | |
|---|---|
| Market cap | ₹55.17b |
| Earnings (TTM) | ₹2.17b |
| Revenue (TTM) | ₹18.58b |
25.4x
P/E Ratio3.0x
P/S RatioIs AARTIPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AARTIPHARM income statement (TTM) | |
|---|---|
| Revenue | ₹18.58b |
| Cost of Revenue | ₹10.21b |
| Gross Profit | ₹8.37b |
| Other Expenses | ₹6.20b |
| Earnings | ₹2.17b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 23.93 |
| Gross Margin | 45.05% |
| Net Profit Margin | 11.68% |
| Debt/Equity Ratio | 15.0% |
How did AARTIPHARM perform over the long term?
See historical performance and comparison